Malignant hyperthermia or hyperpyrexia (Q41406): Difference between revisions
From determinar.ia.br - Determine suas informações
Created a new Item |
Changed label, description and/or aliases in pt-br, en |
||
| description / pt-br | description / pt-br | ||
Hipertermia maligna é um transtorno farmacogenético do músculo esquelético que se apresenta como uma resposta hipermetabólica a gases anestésicos voláteis potentes, como halotano, sevoflurano, desflurano e o relaxante muscular despolarizante succinilcolina, e raramente em humanos, a estresses como exercícios vigorosos e calor. Pode ser causada por uma mutação no gene Receptor 1 da Rionadina. | |||
| description / en | description / en | ||
Malignant hyperthermia is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anaesthetic gases such as halothane, sevoflurane, desflurane and the depolarizing muscle relaxant succinylcholine, and rarely in humans, to stresses such as vigorous exercise and heat. May be caused by a mutation in the Ryonadine Receptor 1 gene. | |||
Revision as of 07:33, 13 August 2026
Malignant hyperthermia is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anaesthetic gases such as halothane, sevoflurane, desflurane and the depolarizing muscle relaxant succinylcholine, and rarely in humans, to stresses such as vigorous exercise and heat. May be caused by a mutation in the Ryonadine Receptor 1 gene.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | 8C78 |
||
| English | Malignant hyperthermia or hyperpyrexia |
Malignant hyperthermia is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anaesthetic gases such as halothane, sevoflurane, desflurane and the depolarizing muscle relaxant succinylcholine, and rarely in humans, to stresses such as vigorous exercise and heat. May be caused by a mutation in the Ryonadine Receptor 1 gene. |
